Area of research
Neurology · Physiology
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Alzheimer's disease research and treatments, and Dementia and Cognitive Impairment Research.
α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease
Toward a biological definition of neuronal and glial synucleinopathies
<i>LRRK2</i> -associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study
Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study
One-step nanoscale expansion microscopy reveals individual protein shapes
Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose‐Driven Approach
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
A Statement of the <scp>MDS</scp> on Biological Definition, Staging, and Classification of Parkinson's Disease
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
A proteogenomic view of Parkinson’s disease causality and heterogeneity
Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
Evaluation of ATN <sub>PD</sub> framework and biofluid markers to predict cognitive decline in early Parkinson’s disease
Trial of Cinpanemab in Early Parkinson’s Disease
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
Antemortem detection of Parkinson’s disease pathology in peripheral biopsies using artificial intelligence
Common Variants Near <scp>ZIC1</scp> and <scp>ZIC4</scp> in Autopsy‐Confirmed Multiple System Atrophy
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies
The Mutation Matters: <scp>CSF</scp> Profiles of <scp>GCase</scp>, Sphingolipids, α‐Synuclein in <scp>PD<sub>GBA</sub></scp>
Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson’s disease progression
Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression